Navigation Links
Lotus Pharmaceuticals, Inc. Purchases Intellectual Property Rights to an Established Prescription Drug
Date:2/18/2009

BEIJING, Feb. 18 /PRNewswire-Asia-FirstCall/ -- Lotus Pharmaceuticals, Inc. (OTC Bulletin Board: LTUS, "Lotus" or the "Company"), a company that controls and operates pharmaceutical companies in the People's Republic of China ("PRC"), today announced that contractually controlled Beijing Liang Fang Pharmaceutical Co., Ltd. ("Liang Fang") entered into an intellectual rights transfer contract with Beijing Yipuan Bio-Medical Technology Co., Ltd. ("Yipuan") in December 2008 to acquire the drug Yipubishan, a highly effective and stable octreotide acetate injection solution, according to a clinical research report issued by Beijing Union Medical College Hospital Center for Clinical Pharmacology, used to treat the symptoms of gastric ulcers and hemorrhages of the upper digestive tract since 2004.

Liang Fang will pay RMB54 million (about $7.9 million) in installments within six months of the date of signing the intellectual rights transfer contract with Yipuan (the intellectual property rights to Yipubishan are documented in an official drug certificate for Yipubishan). Liang Fang has paid RMB20 million (approximately $2.9 million) to Yipuan as of December 31, 2008 and the remaining balance of RMB34 million (approximately $5 million) is due by May 31, 2009. Liang Fang intends to use its present working capital to fund the project.

Part of the development costs of Yipubishan were funded through the use of grants from the Innovation Fund for Small - Medium Technology Based Firms of the Ministry of Science and Technology of the PRC. Because of its advanced bio-medical technology and impact, Yipubishan became the first prescription drug of its kind developed in China to be included in the National Torch Project. The National Torch Project, approved by China State Department, recognizes and promotes commercialization of high-tech discoveries and encourages companies to use high technology.

Estimated thi
'/>"/>

SOURCE Lotus Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. Lotus Pharmaceuticals, Inc. Purchases Land Use Rights to Grow its Business and Reduce Costs
2. Lotus Pharmaceuticals to Present at Rodman & Renshaw Conference
3. Lotus Pharmaceuticals Announces Conference Call to Discuss Second Quarter 2008 Results
4. Lotus Pharmaceuticals, Inc. Reaffirms its Confidence in Meeting its Make Good Target for Fiscal Year 2008
5. Lotus Pharmaceuticals, Inc. Announces Conference Call to Discuss First Quarter 2008 Results
6. Lotus Pharmaceuticals, Inc. Announces Resignation of Director Mel Rothberg
7. Lotus Pharmaceuticals, Inc. Announces Fourth Quarter and Fiscal Year 2007 Results
8. Lotus Pharmaceuticals, Inc. Announces Conference Call to Discuss Fourth Quarter and Fiscal Year 2007 Results
9. Lotus Pharmaceuticals Raises $5 Million in Private Placement
10. Lotus Pharmaceuticals, Inc. Implements Environmentally-friendly Cost Saving Strategies
11. Lotus Blossom Consulting Announces E-Book on Infertility Treatment Financing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/2/2015)... WI (PRWEB) March 02, 2015 ... consultancy focused on quality, regulatory and technical consulting, ... as Chief Operating Officer. , Before joining ... experience leading R&D teams in all aspects of ... leadership positions at Covidien (Medtronic), Regulatory Compliance Associates ...
(Date:3/2/2015)... (PRWEB) March 02, 2015 A true renaissance ... leader of the 1960s cult rock band Khazad Doom, has ... his determination to persevere despite all odds. His motto throughout ... matter what situation or goal was before him. And that ... is now being passed on to a new generation. , ...
(Date:3/2/2015)... 2015 In light of the FDA's ... Xarelto (rivaroxaban) tablets, Ford & Associates Nationwide Legal ... for future users, but may come too late for ... the drug. The FDA has now included the term ... on Xarelto's label. The term “cytolytic hepatitis” has also ...
(Date:3/2/2015)... What are the best practices for writing ... are interviews scheduled, how can physicians best prepare, and ... practicing physicians who are looking for new opportunities can ... the PracticeLink Physician Career Advancement Workshop and Job Fair ... from 5:30 to 8:30 p.m. at the Marriott-Texas Medical ...
(Date:3/2/2015)... Bangladesh (PRWEB) March 02, 2015 The ... of fire safety expert Mark Chubb to serve as ... fire safety operations and training in Bangladesh and guide ... source. , “Mark will ensure that the Alliance ... fire safety programs for Bangladesh garment workers,” said Alliance ...
Breaking Medicine News(10 mins):Health News:Regulatory Compliance Associates® Inc. Welcomes Seyed Khorashahi as Chief Operating Officer 2Health News:Cult Rock Star’s “Got To Make It” Attitude Inspires New Generations 2Health News:Cult Rock Star’s “Got To Make It” Attitude Inspires New Generations 3Health News:Ford & Associates Nationwide Legal Services, A.P.C., Comments on Xarelto Lawsuits Upon FDA Revisions 2Health News:Ford & Associates Nationwide Legal Services, A.P.C., Comments on Xarelto Lawsuits Upon FDA Revisions 3Health News:Ford & Associates Nationwide Legal Services, A.P.C., Comments on Xarelto Lawsuits Upon FDA Revisions 4Health News:PracticeLink to Host a Career Advancement Workshop and Job Fair in Houston 2Health News:Alliance for Bangladesh Worker Safety Names New Chief Safety Officer 2
... front of TV, computer linked to less bonding with peers, ... Too much time in front of computers or televisions increases ... parents and peers, a new study suggests. , The researchers ... who provided details about how they spent their free time ...
... resulting aspirin therapy, may not be needed for healthier patients ... study raises questions about the value of both the ankle-brachial ... blood vessel problems in the legs, and the common practice ... ankle-brachial index (ABI) measures blood pressure in the arm and ...
... ... ... ... ...
... , ... ... , , ... ...
... ... ... ... ...
... , ... , ... , , , , ... ...
Cached Medicine News:Health News:Screen Time May Take a Toll on Kids' Relationships 2Health News:Study Questions Value of Test for Peripheral Artery Disease 2Health News:Study Questions Value of Test for Peripheral Artery Disease 3Health News:Sodexo Names Patricia Bellinger to North America Advisory Board 2Health News:Sodexo Names Patricia Bellinger to North America Advisory Board 3Health News:Sodexo Names Patricia Bellinger to North America Advisory Board 4Health News:IDEXX Laboratories Elects Joseph Vumbacco as Director 2Health News:IDEXX Laboratories Elects Joseph Vumbacco as Director 3Health News:New Data from Caldolor(R) Study in Burn Patients to be Presented at 42nd Annual Meeting of The American Burn Association 2Health News:New Data from Caldolor(R) Study in Burn Patients to be Presented at 42nd Annual Meeting of The American Burn Association 3Health News:New Data from Caldolor(R) Study in Burn Patients to be Presented at 42nd Annual Meeting of The American Burn Association 4Health News:New Data from Caldolor(R) Study in Burn Patients to be Presented at 42nd Annual Meeting of The American Burn Association 5Health News:AMA Honors Maine Governor John Baldacci With Top Government Service Award 2Health News:AMA Honors Maine Governor John Baldacci With Top Government Service Award 3
(Date:3/1/2015)... -- LifeScienceIndustryResearch.com announces Global Angiographic X-ray ... pages along with 8 company profiles added to ... 2015 Market Research Report on Global Angiographic X-ray ... report on Global Angiographic X-ray System market.  For ... basic information including definition, classification, application, industry chain ...
(Date:3/1/2015)... 1, 2015 /CNW Telbec/ -   Ergoresearch Ltd (TSXV: ... and known under the « Équilibre, orthèses et ... quarter Ended on December 31, 2014. All dollar amounts ... Revenues for the second quarter of fiscal ... $ 4 095 112 decreasing by 8,8 % compared to revenues of ...
(Date:3/1/2015)... March 1, 2015  An innovative interventional radiology ... sufferers sustained relief of their headaches, according to ... Interventional Radiology ,s Annual Scientific Meeting . ... University New York Empire State College in Saratoga ... ganglion (SPG) blocks to give patients enough ongoing ...
Breaking Medicine Technology:Global Angiographic X-ray System Industry Research Report 2Global Angiographic X-ray System Industry Research Report 3Global Angiographic X-ray System Industry Research Report 4Global Angiographic X-ray System Industry Research Report 5Second Quarter results - Fiscal 2015 - Ergoresearch reports its results for the quarter ended December 31, 2014. 2Second Quarter results - Fiscal 2015 - Ergoresearch reports its results for the quarter ended December 31, 2014. 3Second Quarter results - Fiscal 2015 - Ergoresearch reports its results for the quarter ended December 31, 2014. 4Image-guided treatment shown to break the migraine cycle 2Image-guided treatment shown to break the migraine cycle 3Image-guided treatment shown to break the migraine cycle 4
...  Boston Scientific Corporation (NYSE: BSX ) ... Chromium Coronary Stent System demonstrated non-inferior results in ... at one year compared to the PROMUS Element™ ... First Human Use Trial.  The trial reported one-year ...
... is pleased to announce the acquisition of Assured Packaging, ... custom manufacturer of aerosols for the health and beauty ... Assured Packaging acquisition and the purchase of K-G Spray-Pak ... most diversified custom aerosol filler in Canada. ...
Cached Medicine Technology:One-Year EVOLVE Trial Clinical Results Confirm Comparable Safety And Effectiveness Data Of The Boston Scientific SYNERGY™ Stent Versus PROMUS Element™ Platinum Chromium Stent 2One-Year EVOLVE Trial Clinical Results Confirm Comparable Safety And Effectiveness Data Of The Boston Scientific SYNERGY™ Stent Versus PROMUS Element™ Platinum Chromium Stent 3One-Year EVOLVE Trial Clinical Results Confirm Comparable Safety And Effectiveness Data Of The Boston Scientific SYNERGY™ Stent Versus PROMUS Element™ Platinum Chromium Stent 4One-Year EVOLVE Trial Clinical Results Confirm Comparable Safety And Effectiveness Data Of The Boston Scientific SYNERGY™ Stent Versus PROMUS Element™ Platinum Chromium Stent 5One-Year EVOLVE Trial Clinical Results Confirm Comparable Safety And Effectiveness Data Of The Boston Scientific SYNERGY™ Stent Versus PROMUS Element™ Platinum Chromium Stent 6PLZ Aeroscience Acquires Assured Packaging 2
... Liquichek Qualitative Urine Toxicology Control is ... qualitative rapid urine drug screen panels, including ... (DOA) test kits like Bio-Rad TOX/See, Biosite ... includes qualitative results (+/) for popular kits ...
... Stain is an aqueous new ... in manual methods of reticulocyte ... a one year shelf life ... can be used in conjunction ...
... Liquichek ToRCH Plus IgM ... potential problems in your ToRCH ... affect your test results. Liquichek ... the perfect complement to Liquichek ...
... Liquichek ToRCH Plus Control is ... to monitor the performance of ... instruments and assays. A weak ... allow you to monitor the ...
Medicine Products: